Cited by 50Mesenchymal stem cell researchCancer Cells and MetastasisHematopoietic Stem Cell Transplantation

Human Mesenchymal Stem Cells Are Resistant to Paclitaxel by Adopting a Non-Proliferative Fibroblastic State

Open access
Bosco, Dale B., Kenworthy, Rachael, Zorio, Diego A. R., Sang, Qing-Xiang Amy·2015·PLOS ONE

Abstract

Human mesenchymal stem cell (hMSC) resistance to the apoptotic effects of chemotherapeutic drugs has been of major interest, as these cells can confer this resistance to tumor microenvironments. However, the effects of internalized chemotherapeutics upon hMSCs remain largely unexplored. In this study, cellular viability and proliferation assays, combined with different biochemical approaches, were used to investigate the effects of Paclitaxel exposure upon hMSCs. Our results indicate that hMSCs are highly resistant to the cytotoxic effects of Paclitaxel treatment, even though there was no detectable expression of the efflux pump P-glycoprotein, the usual means by which a cell resists Paclitaxel treatment. Moreover, Paclitaxel treatment induces hMSCs to adopt a non-proliferative fibroblastic state, as evidenced by changes to morphology, cellular markers, and a reduction in differentiation potential that is not directly coupled to the cytoskeletal effects of Paclitaxel. Taken together, our results show that Paclitaxel treatment does not induce apoptosis in hMSCs, but does induce quiescence and phenotypic changes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0128511

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both BM-MSCs and ASCs have the ability to take up certain anti-cancer agents using three main mechanisms: transporters, simple diffusion, and endocytosis.

    “Both BM-MSCs and ASCs have the ability to take up certain anti-cancer agents using three main mechanisms: transporters, simple diffusion, and endocytosis.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [111]

    The Discussion (page not provided) says human MSCs internalize paclitaxel because it can diffuse across the cell membrane. It does not establish uptake by both bone-marrow MSCs and ASCs, or identify transporters and endocytosis as two additional uptake mechanisms. The Results (page not provided) discuss P-glycoprotein as a drug-resistance transporter and report that it was not detected in the treated MSCs, not that it mediates uptake. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Lipophilic anti-cancer agents, such as paclitaxel, are taken up by BM-MSCs and ASCs via simple diffusion.

    “Lipophilic anti-cancer agents, such as paclitaxel, were taken up by BM-MSCs and ASCs via a simple diffusion [109,111].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [111]

    The Discussion (page not available in our copy) says hMSCs internalize paclitaxel because its lipophilic nature allows easy diffusion across the cell membrane. It does not establish this uptake mechanism for adipose-derived stem cells (ASCs) or for lipophilic anticancer agents generally. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bosco, D. B., Kenworthy, R., Zorio, D. A. R., & Sang, Q.-X. A.
Affiliations
Florida State University (US)
Corresponding author
  • Zorio, Diego A. R.
  • Sang, Qing-Xiang Amy
Venue
PLOS ONE
Published
2015-06-01
Volume
10
Issue
6
Pages
e0128511
ISSN
1932-6203 (ISSN-L)
OpenAlex
W639465351
Cited by
50
References
55
Citations by year
2026: 1 · 2025: 1 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 8 · 2017: 5 · 2015: 2
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Florida State University
  • Tulane University
  • Sun Yat-sen University
  • Sun Yat-sen University Cancer Center
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
human mesenchymal stem cells, paclitaxel, drug resistance, quiescence, P-glycoprotein, apoptosis, differentiation potential, cytoskeleton, tumor microenvironment, chemotherapy
MeSH terms
Antineoplastic Agents, Phytogenic, Cell Differentiation, Fibroblasts, Humans, Protein Binding, Paclitaxel, Adipocytes, ATP Binding Cassette Transporter, Subfamily B, Member 1, Cell Proliferation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review